ERBB2 and cancer: While they found no difference between pCR rates in white and non-white women with ER+ or PR+ tumors, they noted a lower pCR rate in AA women with ER-/PR-/HER2+ cancers (43% v 54%, p=0.001) and TNBC (37% v 43%, p<0.001) compared to white women.